Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease

BACKGROUND: As investigations of disease modifying drugs aim to slow down progression of Alzheimer’ disease (AD) biomarkers to reliably track disease progression gain more importance. This is especially important as clinical symptoms, including psychometric measures, are only modestly associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortner, Marion, Drost, René, Heddderich, Dennis, Goldhardt, Oliver, Müller-Sarnowski, Felix, Diehl-Schmid, Janine, Förstl, Hans, Yakushev, Igor, Grimmer, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822351/
https://www.ncbi.nlm.nih.gov/pubmed/31672138
http://dx.doi.org/10.1186/s12883-019-1498-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822351/
https://www.ncbi.nlm.nih.gov/pubmed/31672138
http://dx.doi.org/10.1186/s12883-019-1498-9

Ejemplares similares